Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track
Results from LUCIDITY
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it will host an investor event at the ObesityWeek® Annual Meeting on November 15, 2026, at 11:45 a.m. ET, both
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will participate in the following upcoming investor conferences, which are being conducted
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its third quarter 2026 financial results on Thursday, November 5, 2026. Amylyx’s senior management team will host a
Late-breaking oral presentation to feature Phase 3 topline data highlighting avexitide’s efficacy and safety
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat will take place on
Tortugas Neuroscience ("Tortugas"), a clinical-stage central nervous system (CNS)-focused biotech company developing medicines with clinically validated mechanisms of action in indications with both substantial
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the 24th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition,
LUCIDITY met FDA-agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003)
LUCIDITY met all secondary
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18,
Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated in late August
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its second quarter 2026 financial results on Thursday, August 6, 2026. Amylyx’s senior management team will host a
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
